<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">STS</journal-id>
<journal-id journal-id-type="hwp">spsts</journal-id>
<journal-title>Science, Technology and Society</journal-title>
<issn pub-type="ppub">0971-7218</issn>
<issn pub-type="epub">0973-0796</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage India: New Delhi, India</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/097172181101700107</article-id>
<article-id pub-id-type="publisher-id">10.1177_097172181101700107</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Articles</subject>
<subj-group subj-group-type="heading">
<subject>States, Technologies and ‘Securing the Future’</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Buying In, Edging Out: Perspectives on Contemporary Global Health Financing among Thailand’s Malaria Community</article-title>
</title-group>
<contrib-group content-type="issue">
<contrib contrib-type="guest-editor">
<name><surname>Coopmans</surname><given-names>Catelijne</given-names></name>
</contrib>
<contrib contrib-type="guest-editor">
<name><surname>Graham</surname><given-names>Connor</given-names></name>
</contrib>
<contrib contrib-type="guest-editor">
<name><surname>Gelfert</surname><given-names>Axel</given-names></name>
</contrib>
<contrib contrib-type="guest-editor">
<name><surname>Clancey</surname><given-names>Gregory</given-names></name>
</contrib>
</contrib-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Buergi</surname><given-names>Birgit R.</given-names></name>
</contrib>
<aff id="aff1-097172181101700107">Birgit R. Buergi, Department of Sociology, Faculty of Arts &amp; Social Sciences, National University of Singapore. E-mail: <email>birgit.buergi@cantab.net</email></aff>
</contrib-group>
<pub-date pub-type="epub-ppub">
<month>3</month>
<year>2012</year>
</pub-date>
<volume>17</volume>
<issue>1</issue>
<issue-title>Special Issue: Technologies, Lives and Futures in Asia</issue-title>
<fpage>123</fpage>
<lpage>142</lpage>
<permissions>
<copyright-statement>© 2012 SAGE Publications</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<p>The first signs of an unprecedented form of drug resistance, identified along the Thai–Cambodia border, have reawakened scientific interest in the discovery of new anti-malarial treatments. Innovation in malaria financing policy geared to promote wider access to effective and safe malaria drugs through coordinated investment practices of large global health donors has significantly contributed to invigorate international product research and development (R&amp;D). This article seeks to explore the elementary question of what the increment in global funding for malaria control and elimination has done, not for, but to the Thai malaria policy and research community. Drawing on ethnographic research, it first examines how public–private partnership arrangements in this bioscientific and biomedical field have helped close the product innovation cycle of a non-profit-based drug developer. Second, it asks in what ways the successful resolution of an earlier disjunction between drug safety and efficacy studies and drug discovery has impinged on the working relationships between two local communities of practice. I set out my notion of ‘disconnected connectivities’ to analyze this dynamic between the global and the local to elucidate how the global inclusivity that collaborative financing instruments and mechanisms provide spurs unanticipated forms of exclusion within the international malaria science enterprise.</p>
</abstract>
</article-meta>
</front>
<back>
<ref-list>
<title>References</title>
<ref id="bibr1-097172181101700107">
<citation citation-type="book">
<person-group person-group-type="editor">
<name><surname>Arrow</surname><given-names>K.J.</given-names></name>
<name><surname>Panosian</surname><given-names>C.B.</given-names></name>
<name><surname>Gelband</surname><given-names>H.</given-names></name>
</person-group> (Eds). (<year>2004</year>). <source>Saving lives, buying time. Economics of malaria drugs in an age of resistance</source>. <publisher-loc>Washington DC</publisher-loc>: <publisher-name>The National Academic Press</publisher-name>.</citation>
</ref>
<ref id="bibr2-097172181101700107">
<citation citation-type="web">
<person-group person-group-type="author">
<name><surname>Chan</surname><given-names>M.</given-names></name>
</person-group> (<year>2008</year>). <article-title>Statement made at the launch of the World Malaria Report 2008</article-title>. <comment>Geneva, Switzerland, 18 September 2008</comment>. <publisher-loc>Geneva</publisher-loc>: <publisher-name>World Health Organization (WHO)</publisher-name>. <comment>Retrieved from <ext-link ext-link-type="uri" xlink:href="http://www.who.int/dg/speeches/2008/20080918/en/">http://www.who.int/dg/speeches/2008/20080918/en/</ext-link></comment>, <access-date>accessed on 10 July 2010</access-date>.</citation>
</ref>
<ref id="bibr3-097172181101700107">
<citation citation-type="web">
<person-group person-group-type="author">
<name><surname>Chan</surname><given-names>M.</given-names></name>
</person-group> (<year>2010</year>). ‘<article-title>A research agenda for malaria eradication’. Closing remarks</article-title>. <comment>Malaria Eradication Research Agenda (malERA) Zenith Week Meeting, Washington, DC, USA, 26 March 2010.</comment> <publisher-loc>Geneva</publisher-loc>: <publisher-name>WHO</publisher-name>. <comment>Retrieved from <ext-link ext-link-type="uri" xlink:href="http://www.who.int/dg/speeches/2010/malaria_20100326/en/index.html">http://www.who.int/dg/speeches/2010/malaria_20100326/en/index.html</ext-link></comment>, <access-date>accessed on 10 July 2010</access-date>.</citation>
</ref>
<ref id="bibr4-097172181101700107">
<citation citation-type="web">
<person-group person-group-type="author">
<name><surname>Coll-Seck</surname><given-names>A.</given-names></name>
</person-group> (<year>2008</year>). <article-title>A golden age for malaria research and innovation</article-title>. [<comment>Online</comment>] <source>Malaria Journal</source>, <volume>7</volume>, <supplement>Suppl. 1</supplement>, <fpage>S2</fpage>. <publisher-loc>London</publisher-loc>: <source>Malaria Journal</source>. <comment>Available at: <ext-link ext-link-type="uri" xlink:href="http://www.malariajournal.com/content/7/S1/S2">http://www.malariajournal.com/content/7/S1/S2</ext-link></comment>, <access-date>accessed on 10 July 2010</access-date>.</citation>
</ref>
<ref id="bibr5-097172181101700107">
<citation citation-type="web">
<person-group person-group-type="author">
<name><surname>Delacollette</surname><given-names>C.</given-names></name>
</person-group> (<year>2009</year>). ‘<article-title>Addressing multi-drug resistance from a Greater Mekong sub-regional perspective: A global priority</article-title>’. <source>ACT Malaria News</source>, <volume>12</volume>(<issue>5</issue>), <volume>6</volume> (<issue>September–October 2009</issue>), <publisher-loc>Manila</publisher-loc>: <publisher-name>ACT Malaria</publisher-name>. <comment>Retrieved from <ext-link ext-link-type="uri" xlink:href="http://www.actmalaria.net/forum2/viewtopic.php?f=29&amp;t=265">http://www.actmalaria.net/forum2/viewtopic.php?f=29&amp;t=265</ext-link></comment>, <access-date>accessed on 10 July 2010</access-date>.</citation>
</ref>
<ref id="bibr6-097172181101700107">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ehrhardt</surname><given-names>S.</given-names></name>
<name><surname>Meyer</surname><given-names>C.G</given-names></name>
</person-group>. (<year>2009</year>). ‘<article-title>Artemether–lumefantrine in the treatment of uncomplicated <italic>Plasmodium falciparum</italic> malaria</article-title>’. <source>Therapeutics and Clinical Risk Management</source>, <volume>5</volume>(<issue>1</issue>), <fpage>805</fpage>–<lpage>15</lpage>.</citation>
</ref>
<ref id="bibr7-097172181101700107">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Enserink</surname><given-names>M.</given-names></name>
</person-group> (<year>2010</year>). ‘<article-title>Malaria’s drug miracle in danger</article-title>’. <source>Science</source>, <volume>328</volume>(<issue>5980</issue>), <fpage>844</fpage>–<lpage>46</lpage>.</citation>
</ref>
<ref id="bibr8-097172181101700107">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Garnier</surname><given-names>J.P.</given-names></name>
</person-group> (<year>2008</year>). ‘<article-title>Rebuilding the R&amp;D engine in big pharma</article-title>’. <source>Harvard Business Review</source>, <month>May</month> <volume>2008</volume>, <fpage>69</fpage>–<lpage>76</lpage>.</citation>
</ref>
<ref id="bibr9-097172181101700107">
<citation citation-type="book">
<collab>Global Forum for Health Research (GFHR)</collab>. (<year>1999</year>). <source>The 10/90 report on health research 1999</source>. <publisher-loc>Geneva</publisher-loc>: <publisher-name>GFHR</publisher-name>.</citation>
</ref>
<ref id="bibr10-097172181101700107">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Guha-Sapir</surname><given-names>D.</given-names></name>
</person-group> (<year>2009</year>). ‘<article-title>The Gates Foundation: Looking at the bigger picture</article-title>’. <source>The Lancet</source>, <volume>374</volume>(<issue>9685</issue>), <fpage>201</fpage>–<lpage>02</lpage>.</citation>
</ref>
<ref id="bibr11-097172181101700107">
<citation citation-type="book">
<collab>House of Commons</collab>. (<year>2008</year>). ‘<article-title>Delivering malaria control to those in need: how to succeed in a time of renewed hope</article-title>’. <comment>6th report of the All-Party Parliamentary Malaria Group (APPMG)</comment>. <publisher-loc>London</publisher-loc>: <publisher-name>House of Commons</publisher-name>.</citation>
</ref>
<ref id="bibr12-097172181101700107">
<citation citation-type="book">
<collab>House of Commons</collab>. (<year>2007a</year>). ‘<article-title>Financing mechanisms for malaria</article-title>’. <comment>Report of the APPMG</comment>. <publisher-loc>London</publisher-loc>: <publisher-name>House of Commons</publisher-name>.</citation>
</ref>
<ref id="bibr13-097172181101700107">
<citation citation-type="book">
<collab>House of Commons</collab>. (<year>2007b</year>). ‘<article-title>The right drug at the right time: The power of the Affordable Medicines Facility-malaria (AMFm) to save lives</article-title>’. <comment>Report for the APPMG</comment>. <publisher-loc>London</publisher-loc>: <publisher-name>House of Commons</publisher-name>.</citation>
</ref>
<ref id="bibr14-097172181101700107">
<citation citation-type="web">
<person-group person-group-type="author">
<name><surname>Kenneth</surname><given-names>D.V.</given-names></name>
<name><surname>Levashina</surname><given-names>E.A.</given-names></name>
<name><surname>Killeen</surname><given-names>G.</given-names></name>
<name><surname>James</surname><given-names>A.A.</given-names></name>
</person-group> (<year>2010</year>). ‘<article-title>Molecular targets for control of vector-borne diseases: Bridging lab and field research</article-title>’. <conf-name>Keystone Symposium, Copper Mountain, Colorado</conf-name>, <conf-loc>USA</conf-loc>. <conf-date>11–16 April 2010</conf-date>. <comment>Retrieved from <ext-link ext-link-type="uri" xlink:href="http://www.keystonesymposia.org/Meetings/ViewPastMeetings.cfm?MeetingID=993">http://www.keystonesymposia.org/Meetings/ViewPastMeetings.cfm?MeetingID=993</ext-link></comment>, <access-date>accessed on 10 November 2011</access-date>.</citation>
</ref>
<ref id="bibr15-097172181101700107">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Keusch</surname><given-names>G.T.</given-names></name>
<name><surname>Kilama</surname><given-names>W.L.</given-names></name>
<name><surname>Moon</surname><given-names>S.</given-names></name>
<name><surname>Szlezák</surname><given-names>N.A.</given-names></name>
<name><surname>Michaud</surname><given-names>C.M.</given-names></name>
</person-group> (<year>2010</year>). ‘<article-title>The global health system: Linking knowledge with action—learning from malaria</article-title>’. <source>PLoS Medicine</source>, <volume>7</volume>(<issue>1</issue>).</citation>
</ref>
<ref id="bibr16-097172181101700107">
<citation citation-type="book">
<person-group person-group-type="editor">
<name><surname>Konrad</surname><given-names>M.</given-names></name>
</person-group> (Ed.). (<year>c2012</year>). <source>Collaborators collaborating: Counterparts in anthropological knowledge and international research relations</source>. <publisher-loc>New York</publisher-loc>: <publisher-name>Berghahn Books</publisher-name>.</citation>
</ref>
<ref id="bibr17-097172181101700107">
<citation citation-type="book">
<person-group person-group-type="author">
<name><surname>Latour</surname><given-names>B.</given-names></name>
</person-group> (<year>1987</year>). <source>Science in action: How to follow scientists and engineers through society</source>. <publisher-loc>Cambridge, Mass.</publisher-loc>: <publisher-name>Harvard University Press</publisher-name>.</citation>
</ref>
<ref id="bibr18-097172181101700107">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Malaney</surname><given-names>P.</given-names></name>
<name><surname>Spielman</surname><given-names>A.</given-names></name>
<name><surname>Sachs</surname><given-names>J.D.</given-names></name>
</person-group> (<year>2004</year>). ‘<article-title>The malaria gap</article-title>’. <source>American Journal of Tropical Medicine and Hygiene</source>, <volume>71</volume>(<supplement>Suppl. 2</supplement>), <fpage>141</fpage>-<lpage>46</lpage>.</citation>
</ref>
<ref id="bibr19-097172181101700107">
<citation citation-type="web">
<person-group person-group-type="author">
<name><surname>Maude</surname><given-names>R.J.</given-names></name>
<name><surname>Pontavornpinyo</surname><given-names>W.</given-names></name>
<name><surname>Saralamba</surname><given-names>S.</given-names></name>
<name><surname>Aguas</surname><given-names>R.</given-names></name>
<name><surname>Yeung</surname><given-names>S.</given-names></name>
<name><surname>Dondorp</surname><given-names>A.M.</given-names></name>
<name><surname>Day</surname><given-names>N.P.</given-names></name>
<name><surname>White</surname><given-names>N.J.</given-names></name>
</person-group> (<year>2009</year>). ‘<article-title>The last man standing is the most resistant: Eliminating artemisinin-resistant malaria in Cambodia</article-title>’. <source>Malaria Journal</source>, <volume>8</volume>, <fpage>31</fpage>. <comment>Retrieved from <ext-link ext-link-type="uri" xlink:href="http://www.malariajournal.com/content/8/1/31">http://www.malariajournal.com/content/8/1/31</ext-link></comment>, <access-date>accessed on 31 October 2011</access-date>.</citation>
</ref>
<ref id="bibr20-097172181101700107">
<citation citation-type="web">
<collab>Medicines for Malaria Venture (MMV)</collab>. (<year>2011</year>). <source>Annual report 2010</source>. <publisher-loc>Geneva</publisher-loc>: <publisher-name>MMV</publisher-name>. <comment>Retrieved from <ext-link ext-link-type="uri" xlink:href="http://www.mmv.org/sites/default/files/uploads/docs/publications/MMV_Annual_Report_2010.pdf">http://www.mmv.org/sites/default/files/uploads/docs/publications/MMV_Annual_Report_2010.pdf</ext-link></comment>, <access-date>accessed on 31 October 2011</access-date>.</citation>
</ref>
<ref id="bibr21-097172181101700107">
<citation citation-type="web">
<collab>Medicines for Malaria Venture (MMV)</collab>. (<year>2005</year>). ‘<article-title>Strategic consultation: Selection of partners for anti-malarial drug combinations</article-title>’. <comment>Position paper. Meeting, Geneva, Switzerland, 29 January 2005</comment>. <publisher-loc>Geneva</publisher-loc>: <publisher-name>MMV</publisher-name>. <comment>Retrieved from <ext-link ext-link-type="uri" xlink:href="http://mmv.org/IMG/pdf/Combinations_Final_Version__8_.pdf">http://mmv.org/IMG/pdf/Combinations_Final_Version__8_.pdf</ext-link></comment>, <access-date>accessed on 26 February 2008</access-date>, <comment>no longer available</comment>.</citation>
</ref>
<ref id="bibr22-097172181101700107">
<citation citation-type="web">
<collab>Medicines for Malaria Venture (MMV)</collab>. (<year>2001</year>). <source>Annual report 2000</source>. <publisher-loc>Geneva</publisher-loc>: <publisher-name>MMV</publisher-name>. <comment>Retrieved from <ext-link ext-link-type="uri" xlink:href="http://www.mmv.org/sites/default/files/uploads/docs/publications/9%20-%20annual_report_2000.pdf">http://www.mmv.org/sites/default/files/uploads/docs/publications/9%20-%20annual_report_2000.pdf</ext-link></comment>, <access-date>accessed on 31 October 2011</access-date>.</citation>
</ref>
<ref id="bibr23-097172181101700107">
<citation citation-type="book">
<collab>National Science and Technology Policy Committee (NSTPC)</collab>. (<year>2004</year>). <source>The National Science and Technology Strategic Plan (2004–2013)</source>. <publisher-loc>Bangkok</publisher-loc>: <publisher-name>National Science and Technology Development Agency (NSTDA)</publisher-name>.</citation>
</ref>
<ref id="bibr24-097172181101700107">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Nwaka</surname><given-names>S.</given-names></name>
<name><surname>Ramirez</surname><given-names>B.</given-names></name>
<name><surname>Brun</surname><given-names>R.</given-names></name>
<name><surname>Maes</surname><given-names>L.</given-names></name>
<name><surname>Douglas</surname><given-names>F.</given-names></name>
<name><surname>Ridley</surname><given-names>R.</given-names></name>
</person-group> (<year>2009</year>). ‘<article-title>Advancing drug innovation for neglected diseases: Criteria for lead progression</article-title>’. <source>PLoS Neglected Tropical Diseases</source>, <volume>3</volume>(<issue>8</issue>), <fpage>e440</fpage>.</citation>
</ref>
<ref id="bibr25-097172181101700107">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Olliaro</surname><given-names>P.</given-names></name>
<name><surname>Wells</surname><given-names>T.N.C.</given-names></name>
</person-group> (<year>2009</year>). ‘<article-title>The global portfolio of new anti-malarial medicines under development</article-title>’. <source>Clinical Pharmacology &amp; Therapeutics</source>, <volume>85</volume>(<issue>6</issue>), <fpage>584</fpage>–<lpage>95</lpage>.</citation>
</ref>
<ref id="bibr26-097172181101700107">
<citation citation-type="book">
<person-group person-group-type="author">
<name><surname>Pearson</surname><given-names>M.</given-names></name>
<name><surname>Hanson</surname><given-names>K.</given-names></name>
<name><surname>Goodman</surname><given-names>C.</given-names></name>
</person-group> (<year>2008</year>). <source>AMFm—Economic appraisal and access by the poor</source>. <publisher-loc>London</publisher-loc>: <publisher-name>DFID Health Resource Centre</publisher-name>.</citation>
</ref>
<ref id="bibr27-097172181101700107">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Petty</surname><given-names>J.</given-names></name>
<name><surname>Heimer</surname><given-names>C.A.</given-names></name>
</person-group> (<year>2011</year>). ‘<article-title>Extending the rails: How research reshapes the clinics</article-title>’. <source>Social Studies of Science</source>, <volume>41</volume>(<issue>3</issue>), <fpage>337</fpage>–<lpage>60</lpage>.</citation>
</ref>
<ref id="bibr28-097172181101700107">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ravishankar</surname><given-names>N.</given-names></name>
<name><surname>Gubbins</surname><given-names>P.</given-names></name>
<name><surname>Cooley</surname><given-names>R.J.</given-names></name>
<name><surname>Leach-Kemon</surname><given-names>K.</given-names></name>
<name><surname>Michaud</surname><given-names>C.M.</given-names></name>
<name><surname>Jamison</surname><given-names>D.T.</given-names></name>
<etal/>
</person-group>. (<year>2009</year>). ‘<article-title>Financing of global health: Tracking development assistance for health from 1990 to 2007</article-title>’. <source>The Lancet</source>, <volume>373</volume>(<issue>9681</issue>), <fpage>2113</fpage>–<lpage>24</lpage>.</citation>
</ref>
<ref id="bibr29-097172181101700107">
<citation citation-type="web">
<collab>Roll Back Malaria (RBM) Partnership</collab>. (<year>2007</year>). <source>Affordable Medicines Facility: Malaria (AMFm): Technical design</source>. <publisher-loc>Geneva</publisher-loc>: <publisher-name>RBM Partnership</publisher-name>. <comment>Retrieved from <ext-link ext-link-type="uri" xlink:href="http://www.rbm.who.int/partnership/tf/globalsubsidy/AMFmTechProposal.pdf">http://www.rbm.who.int/partnership/tf/globalsubsidy/AMFmTechProposal.pdf</ext-link></comment>, <access-date>accessed on 28 October 2011</access-date>.</citation>
</ref>
<ref id="bibr30-097172181101700107">
<citation citation-type="book">
<collab>Roll Back Malaria (RBM) Partnership</collab>. (<year>2008</year>). <source>The Global Malaria Action Plan (GMAP)</source>. <publisher-loc>Geneva</publisher-loc>: <publisher-name>RBM Partnership</publisher-name>.</citation>
</ref>
<ref id="bibr31-097172181101700107">
<citation citation-type="web">
<collab>Roll Back Malaria (RBM) Partnership</collab>. (<year>2011</year>). <source>Progress and Impact Series</source> (<comment>Number</comment> <day>7</day>, <month>September</month> <year>2011</year>). <publisher-loc>Geneva</publisher-loc>: <publisher-name>RBM Partnership</publisher-name>. <comment>Retrieved from <ext-link ext-link-type="uri" xlink:href="http://www.rbm.who.int/ProgressImpactSeries/docs/report8-en.pdf">http://www.rbm.who.int/ProgressImpactSeries/docs/report8-en.pdf</ext-link></comment>, <access-date>accessed on 31 October 2011</access-date>.</citation>
</ref>
<ref id="bibr32-097172181101700107">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sabot</surname><given-names>O.</given-names></name>
<name><surname>Gordon</surname><given-names>M.</given-names></name>
<name><surname>Moonen</surname><given-names>B.</given-names></name>
<name><surname>Talisuna</surname><given-names>A.</given-names></name>
<name><surname>Amofah</surname><given-names>G.</given-names></name>
</person-group> (<year>2011</year>). ‘<article-title>A path to an optimal future for the Affordable Medicines Facility: Malaria</article-title>’. <source>Health Policy Planning</source>, <volume>26</volume>(<issue>6</issue>), <fpage>441</fpage>–<lpage>44</lpage>.</citation>
</ref>
<ref id="bibr33-097172181101700107">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Thurman</surname><given-names>E.B.</given-names></name>
</person-group> (<year>1962</year>). ‘<article-title>Asia: A challenge to scientists</article-title>’. <source>AIBS (American Institute of Biological Sciences) Bulletin</source>, <volume>12</volume>(<issue>1</issue>), <fpage>24</fpage>–<lpage>27</lpage>.</citation>
</ref>
<ref id="bibr34-097172181101700107">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Wells</surname><given-names>T.N.C.</given-names></name>
<name><surname>Alonso</surname><given-names>P.L.</given-names></name>
<name><surname>Gutteridge</surname><given-names>W.E.</given-names></name>
</person-group> (<year>2009</year>). ‘<article-title>New medicines to improve control and contribute to the eradication of malaria</article-title>’. <source>Nature Reviews Drug Discovery</source>, <volume>8</volume>(<issue>11</issue>), <fpage>879</fpage>–<lpage>91</lpage>.</citation>
</ref>
<ref id="bibr35-097172181101700107">
<citation citation-type="book">
<person-group person-group-type="author">
<name><surname>Wenger</surname><given-names>E.</given-names></name>
</person-group> (<year>1998</year>). <source>Communities of practice: Learning, meaning, identity</source>. <publisher-loc>Cambridge</publisher-loc>: <publisher-name>Cambridge University Press</publisher-name>.</citation>
</ref>
<ref id="bibr36-097172181101700107">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>White</surname><given-names>N.J.</given-names></name>
</person-group> (<year>2008</year>). ‘<article-title>The role of anti-malarial drugs in eliminating malaria</article-title>’. <source>Malaria Journal</source>, <volume>7</volume>(<issue>1</issue>), <supplement>Suppl. 1</supplement>, <fpage>S8</fpage>.</citation>
</ref>
<ref id="bibr37-097172181101700107">
<citation citation-type="book">
<person-group person-group-type="author">
<name><surname>Widdus</surname><given-names>R.</given-names></name>
</person-group> (<year>2006</year>). ‘<article-title>Product development partnerships on “neglected diseases”: Intellectual property and improving access to pharmaceuticals for HIV/AIDS, tuberculosis and malaria</article-title>’. In <person-group person-group-type="editor">
<name><surname>Roffe</surname><given-names>R.</given-names></name>
<name><surname>Tansey</surname><given-names>G.</given-names></name>
<name><surname>Vivas-Eugui</surname><given-names>D.</given-names></name>
</person-group> (Eds), <source>Negotiating health: intellectual property and access to medicines</source>. <publisher-loc>London and Sterling, VA</publisher-loc>: <publisher-name>Earthscan</publisher-name>, <fpage>205</fpage>–<lpage>226</lpage>.</citation>
</ref>
<ref id="bibr38-097172181101700107">
<citation citation-type="web">
<collab>World Health Organization (WHO)</collab>. (<year>2011</year>). <source>Global plan for artemisinin resistance containment</source>. <publisher-loc>Geneva</publisher-loc>: <publisher-name>WHO</publisher-name>. <comment>Retrieved from <ext-link ext-link-type="uri" xlink:href="http://www.who.int/malaria/publications/atoz/artemisinin_resistance_containment_2011.pdf">http://www.who.int/malaria/publications/atoz/artemisinin_resistance_containment_2011.pdf</ext-link></comment>, <access-date>accessed on 3 November 2011</access-date>.</citation>
</ref>
<ref id="bibr39-097172181101700107">
<citation citation-type="book">
<collab>World Health Organization (WHO)</collab>. (<year>2010a</year>). <source>Guidelines for the treatment of malaria</source>. <publisher-loc>Geneva</publisher-loc>: <publisher-name>WHO</publisher-name>.</citation>
</ref>
<ref id="bibr40-097172181101700107">
<citation citation-type="book">
<collab>World Health Organization (WHO)</collab>. (<year>2010b</year>). <source>Report of the world health organisation expert working group on research and develop-ment financing</source>. <publisher-loc>Geneva</publisher-loc>: <publisher-name>WHO</publisher-name>.</citation>
</ref>
<ref id="bibr41-097172181101700107">
<citation citation-type="web">
<collab>World Health Organization (WHO), and Medicines for Malaria Venture (MMV)</collab> (<year>2009</year>), <source>Pharmacovigilance guidance for countries participating in AMFm Phase 1</source>. [<comment>Online</comment>] <publisher-loc>Geneva</publisher-loc>: <publisher-name>WHO, &amp; MMV</publisher-name>. <comment>Available at: <ext-link ext-link-type="uri" xlink:href="http://www.rollbackmalaria.org/mmss/docs/PVforAMFM.pdf">http://www.rollbackmalaria.org/mmss/docs/PVforAMFM.pdf</ext-link></comment>, <access-date>accessed on 10 July 2010</access-date>.</citation>
</ref>
</ref-list>
</back>
</article>